Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.01.2023 | Case report

Axicabtagene-ciloleucel/brexucabtagene-autoleucel/tisagenlecleucel

Immune effector cell-associated neurotoxicity syndrome: 9 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Butt OH, et al. Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell-Associated Neurotoxicity Syndrome. JAMA Oncology 8: 1652-1657, No. 11, 17 Nov 2022. Available from: URL: http://oncology.jamanetwork.com/journal.aspx Butt OH, et al. Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell-Associated Neurotoxicity Syndrome. JAMA Oncology 8: 1652-1657, No. 11, 17 Nov 2022. Available from: URL: http://​oncology.​jamanetwork.​com/​journal.​aspx
Metadaten
Titel
Axicabtagene-ciloleucel/brexucabtagene-autoleucel/tisagenlecleucel
Immune effector cell-associated neurotoxicity syndrome: 9 case reports
Publikationsdatum
01.01.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-32347-x

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Multiple drugs

Case report

Multiple drug

Case report

Adalimumab

Case report

Multiple drugs

Case report

Antineoplastics